Interpace Diagnostics Announces Timing of Earnings Release and Investor Conference Call

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company”), a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services, announced today that it will release its 2017 year-end and fourth quarter financial results on Thursday, March 15, 2018 and will host an investor conference call at 4:30 p.m. EDT.

The live webcast and subsequent replay may be accessed by visiting Interpace’s website www.interpacediagnostics.com.

Alternatively, please call 1-888-394-8218 (U.S.) or 1-323-701-0225 (international) to listen to the live conference call. The conference ID number is 5146319. The webcast replay will be available on the company’s website within 24 hours following completion of the call and archived on the company’s website for 90 days.

About Interpace Diagnostics Group, Inc.

Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX™ that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently being “soft launched” with key opinion leaders as we continue to gather data on this assay that will assist us in seeking favorable reimbursement as well as important clinical information. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US and over time can progress to esophageal cancer. The Company’s data base includes data from over 45,000 patients who have been tested using the Company’s current products, including over 15,000 molecular tests for thyroid nodules. Interpace has been designated as one of the top 20 companies for providing bioinformatics solutions. Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace’s website at www.interpacediagnostics.com

CONTACTS:

Interpace DiagnosticsInvestor Relations:Paul Kuntz(412) [e-mail]